We have also shown for the first time in ovarian cancer cells that poziotinib, currently in late phase clinical trials for patients with NSCLC and an ERBB2 exon 20 insertion mutation [50], has a similar effect when combined with paclitaxel in ABCB1-overexpressing ovarian cancer cells. Here, ABCB1 is linked to ovarian carcinoma.